Vaccine-Induced Subacute Thyroiditis (De Quervain's) after mRNA Vaccine against SARS-CoV-2: A Case Report and Systematic Review.
ASIA syndrome
De Quervain
SARS-CoV-2 vaccine
thyroiditis
Journal
Infectious disease reports
ISSN: 2036-7430
Titre abrégé: Infect Dis Rep
Pays: Switzerland
ID NLM: 101537203
Informations de publication
Date de publication:
21 Feb 2022
21 Feb 2022
Historique:
received:
08
12
2021
revised:
15
02
2022
accepted:
16
02
2022
entrez:
24
2
2022
pubmed:
25
2
2022
medline:
25
2
2022
Statut:
epublish
Résumé
De Quervain's thyroiditis, sometimes referred to as subacute thyroiditis (SAT), is the most common granulomatous disease of the thyroid, typically found after a viral infection in middle-aged women. The mRNA encoding for the angiotensin-converting enzyme-2 (ACE-2) receptor is expressed in follicular thyroid cells, making them a potential target for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Besides infection, SARS-CoV-2 vaccines have also been implicated in SAT pathogenesis. We present a case of a woman developing SAT following vaccination with Comirnaty by Pfizer Inc. (New-York, USA). We performed a systematic review of similar cases available in the literature to provide a better understanding of the topic. We searched the databases PubMed and Embase and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Patient records were then sorted according to the type of administered vaccine and a statistical analysis of the extracted data was performed. No statistically significant difference between mRNA vaccines and other vaccines in inducing SAT was found, nor was any found in terms of patient demographics, symptoms at presentation, initial, or follow-up blood tests. In our case report, we described the possible association between SARS-CoV-2 mRNA-based vaccine Comirnaty and SAT.
Identifiants
pubmed: 35200445
pii: idr14010018
doi: 10.3390/idr14010018
pmc: PMC8871576
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
142-154Références
Am J Otolaryngol. 2022 Jan-Feb;43(1):103211
pubmed: 34534760
J Ultrasound Med. 2013 Mar;32(3):505-11
pubmed: 23443191
Am Fam Physician. 2000 Feb 15;61(4):1047-52, 1054
pubmed: 10706157
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Med Clin North Am. 2012 Mar;96(2):223-33
pubmed: 22443972
Lupus. 2017 Jun;26(7):675-681
pubmed: 28059022
ACS Nano. 2020 Oct 27;14(10):12522-12537
pubmed: 33034449
Pathol Res Pract. 2002;198(12):833-7
pubmed: 12608662
Cureus. 2020 Dec 26;12(12):e12301
pubmed: 33510992
Hum Vaccin Immunother. 2021 Nov 2;17(11):4090-4092
pubmed: 34196589
J Clin Endocrinol Metab. 2021 Aug 18;106(9):2600-2605
pubmed: 34043800
Cureus. 2021 Jun 29;13(6):e16045
pubmed: 34235030
Diagn Cytopathol. 2019 Dec;47(12):1251-1258
pubmed: 31368258
J Endocrinol Invest. 2021 May;44(5):1085-1090
pubmed: 33025553
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Front Med (Lausanne). 2021 Aug 24;8:737142
pubmed: 34504856
SN Compr Clin Med. 2021 Apr 29;:1-13
pubmed: 33942028
Lancet Diabetes Endocrinol. 2020 Sep;8(9):739-741
pubmed: 32738929
Viruses. 2021 Jan 14;13(1):
pubmed: 33466921
Am J Otolaryngol. 2016 Nov - Dec;37(6):534-537
pubmed: 27686396
Hum Pathol. 2007 Jan;38(1):95-102
pubmed: 16996569
Ann Clin Lab Sci. 2017 Sep;47(5):620-624
pubmed: 29066492
Eur Thyroid J. 2021 Feb;9(6):321-323
pubmed: 33708633